Semler Scientific Q2 revenue beats estimates

Semler Scientific

04/08/2025 21:12

Overview

Semler Scientific Q2 revenue declines 43% yr/yr, beats analyst expectations, per LSEG data

Net income for Q2 rises to $66.9 mln, driven by Bitcoin gains

Company achieves 29% BTC yield in Q2, launches CardioVanta subsidiary during Q2

Outlook

Company continues to focus on Bitcoin treasury strategy

Semler Scientific emphasizes growth in healthcare via CardioVanta

Company does not provide specific future financial guidance in its press release

Result Drivers

BITCOIN STRATEGY - Unrealized gains from Bitcoin holdings significantly boosted net income

CARDIOVANTA LAUNCH - Launch of CardioVanta subsidiary aims to drive future healthcare initiatives

INCREASED EXPENSES - Operating expenses rose due to stock-based compensation and legal costs related to U.S. Department of Justice investigation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$8.22 mln
$8.10 mln (2 Analysts)
Q2 EPS
$5.04
Q2 Basic EPS
$5.71
Q2 Income From Operations
-$2.05 mln
Q2 Operating Expenses
$10.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Semler Scientific Inc is $98.00, about 64.8% above its August 1 closing price of $34.46

Press Release: ID:nPn8631kQa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)